J Neuroimmunol. 2015 Dec 15;289:56-61. doi: 10.1016/j.jneuroim.2015.10.005. Epub 2015 Oct 14.
Kang H1, Cao S1, Chen T1, Jiang Z2, Liu Z3, Li Z1, Wei Y4, Ai N4, Xu Q1, Lin Q5, Wei S6.
Neuromyelitis optica spectrum disorders (NMOSDs) are blindness-causing neuritis. In NMOSD patients, NMO-IgG evokes astrocytopathy that in turn causes demyelination. While measurement of NMO-IgG titer will help neurologists make the diagnosis of NMOSDs, it is not sufficient to evaluate the severity of astrocytopathy. In this study, we compared the different levels of an astrocyte biomarker in cerebrospinal fluid of NMOSD patients with good or poor recovery, and then linked their differences to the changes in remyelinating promoter (CXCL12) levels. Our results indicate that NMO-IgG down-regulated CXCL12 and impaired the remyelinating process, this may be a mechanism contributing to the poor recovery of NMOSDs.
Copyright © 2015. Published by Elsevier B.V.